Cookie use on MRCVSonline
We use cookies to ensure that we give you the best experience on our website. If you continue without changing your settings, we will assume that you are happy to receive all cookies.
If you would like to forward this story on to a friend, simply fill in the form below and click send.

Your friend's email:
Your email:
Your name:
 
 
Send Cancel

Boehringer announces collaboration with PetMedix
PetMedix's Ky9 platform can rapidly and efficiently generate fully canine therapeutic antibodies.
Partnership will see the development of companion animal antibody therapeutics.

Boehringer Ingelheim has announced a multi-year partnership with PetMedix - a Cambridge-based biopharmaceutical firm - to develop novel and transformative companion animal antibody therapeutics.

The collaboration will see PetMedix undertake discovery activities against a number of key targets and Boehringer Ingelheim will work to develop and bring these therapies to market. The terms of the partnership have not been disclosed. 

PetMedix’s breakthrough approach to therapeutic antibodies has resulted in a number of successful, novel therapies for humans. It is also the only company in the world that has been able to bring this approach to veterinary medicine.

Through its its Ky9™ platform, PetMedix can rapidly and efficiently generate fully canine therapeutic antibodies. This approach saves time and money in drug development, and reduces the risk of certain key adverse events relative to other antibody technologies.

Dr Tom Weaver, CEO of PetMedix, said: “We are excited to be working with Boehringer Ingelheim on this project as we feel we bring complementary experience and expertise to this partnership. PetMedix has developed the leading pet antibody discovery engine, and it will be through Boehringer Ingelheim’s global scale and industry leadership that these novel therapies will best be able to succeed and ultimately benefit the animals.”

James Allan, global head of transaction, business development & licensing, Boehringer Ingelheim Animal Health, added: “Boehringer Ingelheim is pleased to be working with PetMedix on this cutting edge technology as a means to bring innovative new therapies to improve the health of animals globally. PetMedix has a unique expertise and its focus on innovation aligns well with our own”.

Become a member or log in to add this story to your CPD history

New series shares recipes for pet-safe festive treats

News Story 1
 Battersea has launched a new Christmas baking series across all it's social media channels, to teach owners how to make pet-safe treats for dogs and cats.

The two-part series will show dog owners how to make Christmas dog treats using xylitol-free peanut butter and banana. Meanwhile, cat owners will be taught how to use rolled oats and turkey to make a festive snack for their pet.

Battersea also reminds pet owners of the importance of insuring that animals maintain a healthy balanced diet and adds that these food items should only be given as a treat.

To view the series, please visit Battersea's YouTube, Facebook, Twitter or Instagram

Image (c) Battersea. 

Click here for more...
News Shorts
APHA confirms eighth case of highly pathogenic avian influenza in England

The Animal & Plant Health Agency (APHA) has identified an eighth case of highly pathogenic avian influenza (HPAI) H5N8 in poultry in England.

Confirmed on Tuesday (15 December), the outbreak was found in captive birds and poultry at a premises near Willington, South Derbyshire. A 3km Protection Zone and a 10km Surveillance Zone have been placed around the infected premises to limit the risk of the disease spreading.

Further information about the outbreaks and the latest government advice can be found at gov.uk